New contract in Huntington’s disease with US-based pharmaceutical company

IXICO, the digital technologies company serving neuroscience, today announces that it has signed a new contract with a customer for its technology enabled imaging services. The contract value is US$690k over a two and a half year term.

This new contract is for a Phase II clinical trial evaluating the safety and tolerability of a novel treatment for patients with Huntington’s disease. As part of the study, IXICO will use its TrialTracker digital platform and scientific services to provide a battery of advanced MRI imaging techniques and clinical trial endpoints.

By |2017-10-02T12:59:07+00:0028 September 2017|Contracts|